Company: LNAI
Filing Date: 2025-03-06
Form Type: 425
Source: 0001731122-25-000356
Chunk: 3

Company: Lunai Bioworks Inc.
Filing Date: 2025-03-06
Form: 425
Chunk 3
---
 meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding Renovaro’s
proposed business combination transaction with Predictive Oncology, all statements regarding the Renovaro’s expected future financial
position, results of operations, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive
positions, growth opportunities, plans and objectives of management, and statements containing words such as “anticipate,”
“approximate,” “believe,” “plan,” “estimate,” “expect,” “project,”
“could,” “would,” “should,” “will,” “intend,” “may,” “potential,”
“upside,” and other similar expressions. All statements in this Current Report on Form 8-K, including its exhibits, that are
not historical facts, are forward-looking statements that reflect the best judgment of Renovaro based upon currently available information.

Such forward-looking statements
are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from
Renovaro’s expectations as a result of a variety of factors, including, without limitation, those discussed below. Such forward-looking
statements are based upon management’s current expectations and include known and unknown risks, uncertainties and other factors,
many of which Renovaro is unable to predict or control, that may cause its actual results, performance or plans to differ materially from
any future results, performance or plans expressed or implied by such forward-looking statements. These statements involve risks, uncertainties
and other factors discussed below and detailed from time to time in Renovaro’s filings with the SEC.

Risks and uncertainties related
to the proposed Transaction include, but are not limited to, the risk that Predictive Oncology’s stockholders do not approve the
Transaction, potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction,
uncertainties as to the timing of the Transaction, adverse effects on Renovaro’s stock price resulting from the announcement of
the Transaction or the failure of the Transaction to be completed, competitive responses to the announcement of the Transaction, the risk
that regulatory, licensure or other approvals required for the consummation of the Transaction are not obtained or are obtained subject
to terms and conditions that are not anticipated, litigation relating to the Transaction, the inability to